Guggenheim assumed coverage of Kymera Therapeutics (KYMR) with a Buy rating and $90 price target The firm sees a good stock setup into KT-621 Phase 1b atopic dermatitis data disclosure in Q4. Kymera has collected enough information in the first 10 of 20 patients to launch the Phase 2 in October before the Phase 1b completed, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics price target raised to $72 from $54 at BofA
- Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
- Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis
- Kymera Therapeutics presents new preclinical data for KT-579